Ilya Rachman
Chief Executive Officer bei IMMIX BIOPHARMA, INC.
Vermögen: 3 Mio $ am 31.03.2024
Profil
Ilya Rachman is a Chairman & Chief Executive Officer and founder of Immix Biopharma, Inc. which is founded in 2012.
He is also currently an Executive Chairman at Nexcella, Inc. Dr. Rachman has an MBA from the University of California, Los Angeles, a graduate and doctorate degree from the University of Illinois, and an undergraduate degree from the University of Iowa.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
IMMIX BIOPHARMA, INC.
3,53% | 14.08.2023 | 902 500 ( 3,53% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Ilya Rachman
Unternehmen | Position | Beginn |
---|---|---|
IMMIX BIOPHARMA, INC. | Chief Executive Officer | 01.01.2012 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Chairman | - |
Ausbildung von Ilya Rachman
University of California, Los Angeles | Masters Business Admin |
University of Illinois | Doctorate Degree |
University of Iowa | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
IMMIX BIOPHARMA, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |